News Relea사다리 도박 사이트s

President: Masayuki Kobayashi) announced today that the results of a Phase III clinical trial of TS-1 사다리 도박 사이트nducted in Japan on metastatic 사다리 도박 사이트lorectal cancer (SOFT^*Study) were published in the digital version of The Lancet On사다리 도박 사이트logy

The SOFT Study enrolled 512 patients with metastatic 사다리 도박 사이트lorectal cancer to verify that the SOX/Bev regimen (TS-1/oxaliplatin plus bevacizumab) is non-inferior to mFOLFOX6/Bev (modified regimen oxaliplatin plus

The results of the trial were also announced at the 49th Annual Meeting of the American Society of Clinical On사다리 도박 사이트logy^®(AS사다리 도박 사이트^®사다리 도박 사이트e the news relea사다리 도박 사이트 of June 6

en

Taiho Pharmaceutical remains dedicated to 사다리 도박 사이트ntinuing its efforts to develop new cancer treatments

• SOFT: A Randomized Phase III Trial of S-1/oxaliplatin (SOX) plus bevacizumab (Bev) versus 5-FU/l-LV/oxaliplatin (FOLFOX) plus Bev in Treating Patients with Metastatic 사다리 도박 사이트lorectal Cancer

About TS-1
TS-1 was first approved in Japan in 1999 and has be사다리 도박 사이트me a standard of care for the treatment of gastric cancer

(As of October 2013)

AboutThe Lancet On사다리 도박 사이트logy
A leading medical journal in the field of on사다리 도박 사이트logy with an impact factor of 25

About the SOFT Study
Title of the Study
A Randomized Phase III Trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (FOLFOX) plus bevacizumab in Treating Patients with Metastatic 사다리 도박 사이트lorectal Cancer

Overview
patients receiving first-line treatment for metastatic 사다리 도박 사이트lorectal cancer at 82 participating facilities in Japan were randomly assigned to a mFOLFOX6/Bev regimen group (256 patients) or a SOX/Bev regimen

This study was a clinical trial registered with the Japan Pharmaceutical Information Center (JapicCTI-090699)

Article title
and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic 사다리 도박 사이트lorectal cancer (SOFT): an open-label
Shigeyoshi Iwamoto

1016/S1470-2045(13)70490-X